Illinois State University

ISU ReD: Research and eData
Theses and Dissertations
7-2-2019

Potential For On-Site, Prosecutorial Evidence From Drug Residues
Collected On Plasmonic Paper: A Pilot Study For Sers-Psi-Ms
Daniel S. Burr
Illinois State University, daniel.stephen.burr@gmail.com

Follow this and additional works at: https://ir.library.illinoisstate.edu/etd
Part of the Analytical Chemistry Commons, and the Nanoscience and Nanotechnology Commons

Recommended Citation
Burr, Daniel S., "Potential For On-Site, Prosecutorial Evidence From Drug Residues Collected On Plasmonic
Paper: A Pilot Study For Sers-Psi-Ms" (2019). Theses and Dissertations. 1154.
https://ir.library.illinoisstate.edu/etd/1154

This Thesis is brought to you for free and open access by ISU ReD: Research and eData. It has been accepted for
inclusion in Theses and Dissertations by an authorized administrator of ISU ReD: Research and eData. For more
information, please contact ISUReD@ilstu.edu.

POTENTIAL FOR ON-SITE, PROSECUTORIAL EVIDENCE FROM DRUG RESIDUES
COLLECTED ON PLASMONIC PAPER: A PILOT STUDY FOR SERS-PSI-MS

DANIEL S. BURR
67 Pages
Given the potential impact of improvements to on-site drug testing, as well as recent,
successful displays of paper spray ionization mass spectrometry (PSI-MS) in this regard, this
thesis pilots the implementation of Raman spectroscopy as a compliment to MS for field-based
confirmatory drug testing. Surface enhanced Raman scattering (SERS) is utilized for applications
to trace detection. Two-tiered analysis of individual drug samples is enabled using triangularlycut plasmonic papers, from which both SERS and PSI-MS analysis may be performed. Several
drug compounds, representative of traditional and emerging drug types, are examined by these
techniques, both separately and as a fully integrated, SERS-PSI-MS testing platform. Calibration
models for the drugs are constructed, which indicate single-nanogram limits of detection. The
unique benefits offered by Raman/SERS are demonstrated via discrimination of isomers that are
indistinguishable by MS. Finally, optimization of the coupled, analytical platform culminates in
a standard operating procedure. This is implemented in an error-rate study (N = 500) performed
for sub-microgram quantities of drugs, returning a 99.2% success rate.

KEYWORDS: Raman spectroscopy; surface enhanced Raman scattering (SERS); ambient mass
spectrometry; portable forensics; controlled substances; plasmonics
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CHAPTER I: INTRODUCTION
Scope of Forensic Drug Evidence Problem
Data collected by the Bureau of Justice Statistics have shown that, in publicly funded
forensics laboratories, substantial time and effort are exhausted on the routine analysis of suspected
controlled substances.1 In 2014 specifically, drug testing commanded a steady one-third of all
forensics case requests; such testing was similarly represented within the 570,000 national sample
backlog. Increasing sample throughput could expedite confirmatory drug testing, forensics testing
generally, and legal proceedings. Overall, significant public resources could be conserved by
streamlining the handling of drug evidence.
In current practice, drug testing follows a deliberate, nearly universal protocol.2 Evidence
is first encountered by police officers, narcotics agents, or detectives operating in various locales
(e.g. traffic stops, clandestine labs, drug house busts). Once seized, samples are presumptively
identified via a colorimetric field-test. After this they are transported to forensics laboratories for
confirmatory analysis, which is performed using established instrumental techniques – most often
gas chromatography coupled with mass spectrometry (GC-MS).
Though it is relatively straightforward, this process leaves much room for improvement.
The time required for each sample is extensive, spanning seizure, presumptive identification,
transport, time in a work queue, and analysis. Current presumptive tests have multiple
drawbacks,3,4 which allow false positives to be carried through the process until its end, adding
unnecessary work for law enforcement and forensics practitioners. The situation is further
complicated by emerging classes of drugs, e.g. new psychoactive substances (NPSs) and synthetic
opioids.5 There is widespread frenzy regarding how to deal with such substances, which elude
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detection by continuously appearing in derivatized forms, and – owing to their dangerously high
potency – are often present at low concentrations.5
Ultimately, forensics laboratories face a burden they are not equipped to carry. Revisiting
forensics best-practices, along with considering the potential of alternate detection strategies, is
requisite for redirecting this strain from lab to field. The modernization of field-testing – arguably
the best focus for streamlining drug analysis – is an active, widespread research effort.6
Forensic Drug Testing Guidelines
To hold merit in the forensics community, testing strategies must align with established
recommendations, such as those of the Scientific Working Group for the Analysis of Seized Drugs
(SWGDRUG). To establish minimum requirements for accurate, court-admissible drug evidence,
SWGDRUG ranks analytical techniques according to their discriminating power (Table 1). Drug
evidence is deemed admissible only after positive identification by two independent techniques,
as long as one technique resides in Category A.7 Conforming to SWGDRUG recommendations
would be an important benchmark in the development of a novel, on-site drug testing strategy.

Table 1
SWGDRUG categorization of analytical techniques for drug analysis
Category A

Category B

Category C

Infrared spectroscopy (IR)

Capillary electrophoresis (CE)

Color tests

Mass spectrometry (MS)

Gas chromatography (GC)

Fluorescence

Nuclear magnetic resonance

Ion mobility spectrometry (IMS)

Immunoassay

Raman spectroscopy

Liquid chromatography (LC)

Melting point

X-ray diffractometry

Thin layer chromatography (TLC)

UV-vis
spectrophotometry
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Many Category A and B techniques are commercially available in portable formats (e.g.
IR, Raman, MS). Implementation of one such method as an improved presumptive test would
reduce the workload caused by false positives and ambiguous results. However, keeping in mind
SWGDRUG’s two-tiered recommendation, the combined use of two independent portable
techniques could generate admissible evidence entirely in the field.
On-site Detection Strategies
The ability to rapidly, reliably identify samples at the point they are first encountered would
constitute a desirable paradigm shift in the handling of drug evidence. Currently, field-based
testing is limited to colorimetric reagent test kits. Under this methodology, a suspicious sample is
mixed with a reagent cocktail (often Marquis or Scott) that characteristically changes color in the
presence of common drugs of abuse. Such tests are rapid and easy to use, yet they have many
drawbacks, including false positives,3 ambiguous results,4 a lack of chemical specificity,8 and
applicability to only a handful of anticipated analytes. Foregoing colorimetric detection, there is a
repertoire of portable, analytical methods that are inherently more selective and broadly applicable.
It is beyond the scope of this work to review all of them, however, and so focus will be directed
principally towards the Category A techniques of vibrational spectroscopy and portable MS. An
emerging area of portable, trace drug detection, e.g. electrochemical methods – though not yet
ranked by SWGDRUG – is also discussed.
Colorimetric Testing on Paper Analytical Devices
Several methods for overcoming these deficits have been reported. Improved colorimetric
testing has been demonstrated on paper analytical devices (PADs). Notably, one PAD used waxprinted, branched reservoirs of reagents to multiplex color testing.9 This design proffered
additional analytical information while purportedly retaining ease of use. However, the

3

interpretation of such tests quickly becomes complex, with multiple color changes across several
reaction wells. To overcome this difficulty, and improve sensitivity, detection in some of these
systems has been extended beyond visualization – relying instead on computerized detection of
fluorescence or luminescence.10,11 Yet, in these cases, simplistic design and operation are traded
for only modest increases in discriminatory power. If computerized detection is to supersede visual
interpretation, a colorimetric approach loses its fundamental appeal.
Electrochemical Detection
The principle behind electrochemical detection is that drug molecules can be identified
from their oxidation/reduction potentials, which are adequately specific for each molecule.
Electrochemical methods are an emerging trace detection strategy for forensics,12 and have
recently been used for the detection of cocaine (along with its common adulterants),13 new
psychoactive substances,14 and synthetic cannabinoids.15 These methods boast a range of benefits,
including low cost, simplistic design, and commercially available, portable, battery-powered
instrumentation.
Traditionally, electrochemical systems suffer from electrode fouling, limited throughput,
and poor selectivity. Recent work has circumvented these problems in a variety of ways. Electrode
fouling has been mitigated through the use of screen-printed electrodes (SPEs), which simplify the
handling of electrodes and are intended for single or limited use. Additionally, sample throughput
has been improved using batch-injection analysis (BIA) systems.16 Within these systems, small
samples (~50 µL) are injected onto the working electrode in an electrochemical cell within which
a bulk liquid is stirred or flowed. Oxidation/reduction is briefly detected, and while the electrode
is stripped the sample is diluted into the larger volume – readying the cell for the next sample.
Coupling of BIA with SPEs has been used to achieve throughputs of 60 sample injections per
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hour.17 Improvements to selectivity have involved immobilized molecules – enzymes,18
antibodies,19 aptamers,20 and molecular imprinted polymers21 – as well as electrodes on which
drug analytes have an affinity or a particular tendency to be electroactive.22 However, neither of
these improvements to selectivity can be simultaneously optimized for many classes of drug
molecules. Depending on the electrode, some drug molecules may not be electroactive at all.23
Overall, recent advances – along with inherently simple instrumentation – have made portable
electrochemical detection a feasible, promising option. However, electrochemical activity remains
a modestly selective parameter. Furthermore, the best developments in throughput and ease of
operation (BIA-SPE) still require the preparation and pipetting of dissolved samples – these could
be considered detriments toward the goal of field-based use by non-chemists.
Portable, Ambient Ionization Mass Spectrometry
Among portable instrumental techniques for field-based drug analysis, ambient ionization
mass spectrometry (AI-MS) has arguably the most promise, especially for its sensitivity,
selectivity (particularly with tandem MS capabilities), and minimal requirements for sample
manipulation.24-27 Samples are ionized under ambient conditions and transferred through a vacuum
gradient into the instrument for mass analysis and detection. A variety of ambient ionization
methods have been reported during the last two decades, including desorption electrospray
ionization (DESI),28,29 direct analysis in real time (DART),30,31 low temperature plasma (LTP),32,33
and – more recently – paper spray ionization (PSI).34,35
In PSI-MS (Figure 1), sample is deposited onto a piece of triangularly-cut paper (typically
Whatman, blotting, or another. The paper is then positioned in front of an AI-MS, with an applied
potential (usually several kV) between the paper and the inlet capillary. With the addition of
solvent, sample is wicked through the pores until it reaches the tip, whereupon an electrospray is
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formed. Akin to traditional electrospray ionization, it is within this spray that gas-phase analyte
ions are formed and guided into the mass spectrometer.

Figure 1. Representation of the simplistic operation of PSI-MS. A triangularly-cut paper,
containing the sample, is subjected to high voltage and then wetted with solvent. This results in
the generation of an electrospray at the paper tip. Gas phase analyte ions are formed from this
spray and, with minimal positioning requirements, enter the mass spectrometer.

PSI-MS holds some distinct advantages over other AI-MS methods. Firstly, the paperbased ionization source can be used as a swab for collecting samples. This, along with its simplistic
execution, makes PSI-MS very amenable to use by minimally trained personnel. Since PSI
incorporates paper chromatography, it is possible to separate analyte compounds from complex
matrices, as has been demonstrated for dried blood spots and foodstuffs.34,36 Furthermore,
application of PSI to drug analysis on a portable, AI-MS systems has been the subject of extensive
work.37-40
While portable AI-MS is able to meet many of the demands specific to on-site drug
detection, the instrumentation is expensive, and this could be considered prohibitive. However, a
recent statistical model explored the benefits (financial and otherwise) to be anticipated from
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routine use of such a platform.41 While the initial cost is high, the reduced number of false positives
forecast a net reduction in cost. There is thus a strong case that AI-MS is not only analytically
powerful and amenable to field-based drug detection – but that it is also financially viable.
Portable Raman Spectroscopy
Vibrational spectroscopy (IR and Raman) is extremely selective in that it detects the
energies of molecular vibrations. Every molecule’s various functional groups and connectivity
give rise to unique, quantized vibrational energies. Taken together, these energy transitions provide
a molecular fingerprint, which is very useful for chemical identification purposes. For complex
mixtures, where the fingerprints of many compounds overlap, multivariate statistical tools spectra
can be used to deconvolute spectra, allowing the identification of its constituents.42 Vibrational
spectra also display good selectivity in the cases of isomeric compounds43,44 – a challenge for other
highly-selective portable detection strategies (e.g. MS).
Both IR and Raman have long met with success in forensics applications.45 Compared with
IR, however, Raman proffers minimal interference from water, sharp peaks with high signal-tonoise ratio, and instrumentation that tends to be simpler and more affordable (ranging from
~$5,000 – $50,000). Portable Raman spectrometers have been demonstrated in the detection of
various pathogens,46-50 counterfeit pharmaceuticals,51-53 and controlled substances.54-56
One drawback of vibrational spectroscopy is its limited applicability to trace evidence – IR
and Raman are better suited for bulk analysis. AI-MS methods, on the other hand, are sensitive to
nanogram quantities of material. A unique benefit of Raman, however, is that it can be extended
to trace detection through the phenomenon of surface-enhanced Raman scattering (SERS).
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Surface-enhanced Raman Scattering (SERS)
SERS, initially discovered in 1977,57,58 is a phenomenon wherein molecules in close
proximity (single nanometers) to noble-metal nanostructures elicit highly intensified Raman
scattering. Reported enhancement factors (EFs) have ranged from 104 to 1014, and SERS
applications have been reported to reach single molecule sensitivities.59,60 The enabling medium
for this ultrasensitive detection is a suitable SERS – often termed plasmonic – noble metal
substrate.
The conduction band electrons of metal nanostructures tend to behave as collectives –
called plasmons – which can oscillate in frequency with electromagnetic radiation. The specific
wavelength at which plasmons experience maximal oscillations is termed the surface plasmon
resonance (SPR). For noble metals this occurs at visible frequencies. Upon irradiation with visible
light, then, the immediate surroundings of noble metal nanostructures experience highly enhanced
electric fields. Molecules adsorbed onto the surface of these structures, owing to the enhanced
electric fields, scatter Raman photons several orders of magnitude more intensely than under
traditional, bulk conditions.61
SERS Substrates
Since the first investigations into SERS there has been a steady lineage of plasmonic – and
thus surface-enhancing – substrates. This progression is delineated in many SERS reviews, past
and present.62-65 Prerequisite to reviewing the varieties of plasmonic substrates, however, there are
several common metrics to note.
The first of these is the previously mentioned EF, which assesses the degree to which
Raman scattering is increased. Finding a single, adequate definition of EFs has been a challenge
within the SERS community, and many ways of calculating EFs exist and are reported.61 In part
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this is because of the many factors involved in SERS, namely the interactions between analyte and
plasmonic surfaces. Maximal SERS enhancement is observed when molecules are within 1 nm of
the plasmonic surface. Furthermore, specific vibrations closer and more orthogonal to the surface
experience the greatest enhancement. Since different molecules will have different affinities for
the surface and different preferred orientations, the EF is not a one-size-fits-all metric.
Beyond the EF, important assessments of a substrate are the consistency of its performance
from one spot to another (spot-to-spot variation), its reproducibility (batch-to-batch variation), and
its performance with time (stability or day-to-day variation). These are usually reported as percent
relative standard deviations (%RSD) for the intensity of a single peak. For spot-to-spot and batchto-batch variations, values of 10% and lower are usually regarded as excellent. Stability is ideally
on the order of weeks or months, but due to fouling of gold or (especially) silver nanostructures,
the consistent performance of substrates across days or weeks is considered satisfactory.
SERS was a serendipitous discovery by two independent research groups, who both
happened upon anomalously intense signals when using Raman spectroscopy to monitor chemical
activity on electrochemically-roughened silver electrodes.57,58 Due to the simple preparation and
adequate EFs of electrochemically-roughened films, these became common early SERS substrates.
However, batch-to-batch reproducibility is a severe limitation: substrates prepared under identical
conditions can vary in signal intensities by 40%.66
Colloidal suspensions of gold or silver nanoparticles (AuNPs, AgNPs) are very common
SERS substrates. Nanoparticles are synthesized by aqueous reduction of gold or silver salts,
stabilized with a capping agent (usually the same species used in reduction, e.g. citrate), and
aggregated with electrolytes such that the SPR is shifted to the ideal location. This tunability is
both a strength and a weakness for colloidal substrates. The size, geometry, and extent of
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aggregation can all be adjusted to provide strong EFs. However, reproducibility is poor: factors
such as timing and mixing can cause polydispersity in the nanoparticles – and aggregation is a
random process, which is time-dependent and non-specifically triggered.62 Additions of sample to
the delicately-balanced colloids, if they affect the solution as a whole, can cause nanoparticles to
massively aggregate and crash from solution. A way to circumvent this is to immobilize the
nanoparticles on a solid support – even then, however, the aggregation process is difficult to
control, and reproducibility can be an issue.
In order to circumvent problems with reproducibility, many solid-phase nanofabrication
strategies have been used for SERS substrate design. Vapor deposition methods, electron-beam
etching, and nanolithography techniques are among the tools for producing solid-phase plasmonic
substrates with maximal enhancement factors and reproducibility.64 Such rigorous, tightly
controlled synthetic methods were (and are) vital to the advancement of SERS theory. However,
with the time, equipment, and expertise required to prepare such substrates, there has arisen a
separate body of research, directed towards low-cost, high-throughput preparation of plasmonic
substrates. Insofar as such substrates have demonstrated adequate enhancement and
reproducibility, SERS has become an increasingly field-ready technique.
Paper SERS Substrates
Plasmonic paper substrates are at the forefront of low-cost, high-throughput options for
SERS sensing.63,67 Paper is a three-dimensional, porous framework of cellulose fibers. As a result
of this porosity, samples spontaneously wick through it. This makes paper SERS sensing versatile:
reports have leveraged the porous nature of paper for ease of sampling (as dipsticks and swabs),68
as well as for paper chromatography and lateral flow preconcentration.69,70
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Paper has been rendered plasmonic via treatment with Au or Ag colloids, either from
soaking,71,72 spraying,73 or printing.68-70,74 In the former, colloids are directly applied onto paper.
In the latter two, colloids are rendered more viscous – usually with added glycerol – to form a
stable, nanoparticle ink. Self-assembled films, formed at the interface of colloidal nanoparticles
with organic solvents, have also been deposited onto filter papers.75 Alternatively, papers have
been endowed with plasmonic structures in situ, by electroless deposition (e.g., silver-mirror
reaction)76 as well as photo-assisted citrate reduction of AgNO3.77
The challenge for paper SERS substrates has been to demonstrate good enhancement and
reproducibility. Table 2 summarizes some of the metrics achieved by modern plasmonic papers,
all of which are satisfactory. Stability is not reported, nor is throughput – these are among the
important factors for distinction among substrates, all else being equal.
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Table 2
Performance of recently reported plasmonic paper substrates: enhancement factors (EFs), limits
of detection (LODs), percent relative standard deviations (%RSD), and model analytes
Method

Nanoparticle

EF

LOD

%RSD

Analyte

Ref.

Dripping78

AuNS
(nanostar)

1.2 x 107

1 nM

NR

Crystal violet

[78]

Soaking79

AuNR
(nanorod)

5 x 106

140 pg
(swabbing)

NR

1,4-benzenedithiol

[79]

Spraying73

AgNP

2 x 107

NR

14.5%
(spot)

Rhodamine 6G

[73]

Printing68,

AgNP

2 x 105

4 pg

15%
(spot)

EF: Rhodamine 6G
LOD: 1,2-Bis(4pyridyl)ethylene

[68]
[74]

AgNP

NR

50 nM

< 5%
(batch)

Rhodamine B

[75]

AgNP

1.9 x 107

625 nM

8%
(batch)

EF: 4-nitrobenzenethiol
LOD: tyrosine

[76]

AuNP

7.8 x 108

1 pM

7.5%
(batch)

2-naphthalenethiol

[80]

AgNP

2.1 x 107

160 nM

8%
(spot)

Adenine

[77]

74

Selfassembly7
5

Electroless
76

Electroless
80

Photoassisted
deposition

* EF = enhancement factor, LOD = limit of detection, %RSD = percent relative standard deviation,
NR = not reported

SERS for the Detection of Controlled Substances
There are several reviews describing applications of SERS in drug testing, as well as for
forensic science generally, utilizing many of the aforementioned substrates.81,82 Colloidal AuNPs
and AgNPs have been used to detect analytes such as synthetic cannabinoids,83 abused
pharmaceuticals,84 and well known street drugs such as cocaine and MDMA.85 There are fewer
reports of solid-phase SERS substrates (barring paper) used for illegal drugs, but the list of analytes
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is still extensive, including benzodiazepines,86 cocaine,87 and – specifically in the case of AuNPendowed fused-silica capillaries – broad swaths of common narcotics.88,89 Reports on paper SERS
substrates, perhaps since they are geared towards field-based applications, very often include one
or several illegal drug analytes.
SERS-PSI-MS
A satisfactory, field-based forensics testing platform quickly delivers accurate information
while remaining easy, safe, and reliable for non-technical personnel to use under the constraints of
law enforcement settings (e.g. limited time, scant evidence, potentially threatening circumstances).
An ideal system – rising to SWGRUG guidelines – incorporates two independent techniques, such
that evidence can be both screened and confirmed in the field. Generating field-based, courtadmissible evidence would streamline drug analysis, saving significant public resources.
Among the many options for portable detection, Raman/SERS and MS are unparalleled in
sensitivity, selectivity, rapidity, and ease of use. There is overlap between a particularly field-ready
AI-MS technique – PSI-MS – and a maturing SERS technique – the use of paper substrates. Using
plasmonic paper samples could allow for efficient coupling of these two powerful detection
strategies (Figure 2). The remainder of this work reports proof-of-principle efforts to combine
SERS and PSI-MS, performing both techniques from a single plasmonic paper. Prerequisite to this
coupled analysis, SERS is established as a promising compliment to MS in terms of sensitivity
(LODs) and selectivity (discrimination among isomers).
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Figure 2. Scheme for the combined approach to trace drug detection by SERS-PSI-MS. The
enabling medium is a sharp-tipped plasmonic paper, from which both PSI-MS and SERS may
be performed – on a single deposited sample.
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CHAPTER II: EXPERIMENTAL METHODS
Reagents
Tetrachloroauric acid trihydrate (ACS regent grade) and trisodium citrate dihydrate
(99%) were obtained from Acros Organics (New Jersey, USA). Whatman Grade 1 filter paper
(GE Healthcare) was used for all plasmonic paper substrates. 2C-B, cocaine, fentanyl, and
hydrocodone standard solutions were purchased from Cerilliant (Texas, USA) as 1 mg dissolved
in 1 mL of methanol. Psilocin and bufotenine (1 mg) and JWH-018 (5 mg) were purchased from
Cayman Chemical Company (Michigan, USA). All drug samples were DEA-exempt. HPLCgrade methanol and formic acid (99.5%) were acquired from Fisher Scientific (New Jersey,
USA). 18 MΩ water was used for all solvents.
Preparation of Plasmonic Papers
Gold nanoparticles (AuNPs) were prepared by thermal reduction of aqueous
tetrachloroauric acid with citrate. Resulting AuNPs were characterized using an Agilent 8453
UV-vis spectrophotometer to screen for the desired surface plasmon resonance (SPR) peak, in
this case within 535 – 540 nm. Colloids that met this specification were evenly pipetted over
Whatman Grade 1 filter papers – contained in Petri dishes – until each paper was submerged.
Following this, the papers were left to soak for 24 hours in room air, with the petri dishes
partially lidded to avert dust. Papers – now colored purple – were removed and left in room air to
dry (Figure 3). Residual colloids were reevaluated by UV-vis to assess concentration of AuNPs
remaining in suspension. This was used as a rough metric to describe the extent of AuNP loading
on the paper. AuNPs adsorbed onto the paper were also visualized by electron microscopy, using
a FEI Quanta 450 environmental SEM.
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61.2 ± 11.2 nm

(a)

(b)

(c)

500 nm

24 hrs

Figure 3. Process of preparing plasmonic papers. Whatman Grade 1 filter papers (a) are
immersed in colloidal AuNP (b), then removed after 24 hours to dry (c). The inlaid SEM
micrograph shows a single cellulose fiber within a filter paper, onto which AuNPs have
adsorbed and formed small aggregates.

Instrumental Methods
Raman Spectroscopy
Raman spectroscopy was performed on a TSI ProRaman-L, equipped with a 785 nm
laser, fiber optic cable, thermoelectrically-cooled CCD detector (-50 ºC), and 0.5 NA objective,
which focuses the laser to a single, circular spot (d = 100 µm). Power output is adjustable across
the range of ~5 mW – 400 mW. The overall dimensions are 9.5” x 7.25” x 5.25” (L x W x H).
The entire setup, less the computer interface, is displayed in Figure 4.
For experiments involving only Raman/SERS – without coupling to MS – plasmonic
papers were cut with a 3 mm hole punch (Hobby Lobby, Normal, IL). Punched-out samples were
loaded with 1 µL of analyte, placed on a gold or aluminum-covered glass slide (to eliminate
background), pinned down with a 3D-printed sample holder (Figure 4, inlaid), and then analyzed
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on the sample stage. Using a USB power meter (THORlabs, New Jersey, USA), laser power
output was set to either 10 or 15 mW. A syringe pump was attached to a translational knob of the
stage, programmed to an inject/withdraw cycle, and left running during Raman acquisitions. This
caused the sample to move relative to the laser, such that each spectrum was collected along a
1.5 mm path instead of from a single spot.

Sample holder

sample stage

Raman spectrometer

rastering apparatus

power meter
Figure 4. TSI ProRaman-L with attachments. Shown are the power meter, sample stage, and
custom rastering apparatus, as well as 3D-printed sample holder (inlaid). The sample holder
snaps onto a covered glass slide – each square hole accommodates a 3 mm-punched paper,
pinning it down at the edges to ensure it remains at the Raman objective’s focal distance.
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When plotted, all Raman spectra were truncated to include only the fingerprint region
(400 – 1800 cm-1). Additionally, in many cases spectra were normalized or offset for the sake of
comparison. The former was accomplished by scaling the dominant peak in the fingerprint
region of each spectrum to a value of one.
Paper Spray Ionization Mass Spectrometry
Mass spectrometry was performed on a portable FLIR Systems AI-MS 1.2 (Figure 5),
equipped with a cylindrical ion trap (CIT) mass analyzer and tandem MS capabilities. The
instrument operates with unit resolution across the mass range 0 – 4000 m/z. The overall
dimensions are 24” x 20” x 15” (L x W x H), with a weight of 98 lbs.
Plasmonic papers were loosely pinned down atop a grid of isosceles triangles (b x h = 8
mm x 9 mm). A scalpel was then used to trace along the grid. The resulting triangular papers were
separated and placed on glass slides. One µL of drug analyte was pipetted onto individual papers,
which were then dried in room air. Samples were then placed in the PSI source.
In the source, papers were held with a piece of copper, which maintained a +4 kV potential
relative to the inlet capillary. Precluding the formation of an electrospray, 5 µL of spray solvent
was pipetted onto the paper. This solvent consisted of one of two solutions: MeOH and H2O
(50:50) with 0.1% formic acid (v/v) – or acetonitrile and water (9:1) with 0.1% formic acid (v/v).
Once a stable spray was established, an MS base scan was collected, followed by tandem MS scans
as needed.
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Figure 5. FLIR Systems Griffin AI-MS 1.2, with attached Thorlabs optomechanical cage
system. This cage system has been used to accommodate several ionization sources,37 and served
as a scaffold for integrating the Raman spectrometer and a PSI source in the present work.
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Integrated SERS-PSI-MS
Method development and staging. Samples were prepared as individual triangles
loaded with 1 µL samples of one of the five representative drug compounds. Raman spectra were
collected before, during, and after the paper spray process to probe any effects the instruments
might have on one other. The outcomes of these studies lent themselves to design considerations
for the SERS-PSI-MS stage.
The custom-built stage (Figure 6) was constructed using 3D-printed devices (Ultimaker
2+) and optomechanical assemblies (THORLabs, New Jersey, USA) – the latter of which
allowed for fine (µm-scale) adjustments in the vertical and translational axes. Each paper sample
was placed in a 3D-printed, polypropylene strip with an embedded ribbon of copper foil. This
strip was inserted into a channel within the stage, where it could be moved forward or backward
relative to the MS.

Figure 6. Precision sample stage, supplemented with 3D-printed devices, for integrated SERSPSI-MS analysis. At left, the sample strip is slid forward (relative to the MS inlet), initiating
electrical contact and – upon addition of solvent – starting the paper spray process. At right,
the sample strip is slid backward for collection of Raman spectra.
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Standard operating procedure. For operation, triangularly-cut plasmonic papers – onto
which analyte had been deposited and dried – were placed within the polypropylene strips. Strips
were then inserted into the channel of the stage, where they could be slid forward or backward.
In the forward position, electrical contact was formed for PSI-MS. Five µL of MeOH : water
(50:50) with 0.1% formic acid was then pipetted onto the paper, initiating paper spray. Minor
positional adjustments were made as needed to stabilize the spray and maximize signal. In the
backward position, the lights were dimmed for collection of Raman spectra. The initial protocol
was to conduct Raman (nondestructive method) prior to MS (destructive method). However, it
was found that the quality of Raman spectra greatly improved after PSI-MS – perhaps due to
concentration of analyte at the paper tip. The final standard operating procedure reflected this,
such that Raman acquisitions always followed PSI-MS.
SERS Identification of Drugs
Five controlled substances (Figure 7) were chosen to represent common and emerging
drug classes (e.g., new psychoactive substances, traditional drugs of abuse, synthetic opioids,
abused pharmaceuticals, and synthetic cannabinoids). Sections of plasmonic paper were cut out
with a 3 mm hole punch (Hobby Lobby, Normal, IL). In order to probe the potential of SERS for
detecting these substances, 1 µg of each was deposited (as 1 µL of 1 mg/mL standard) on three
respective paper punches. Deposition – rather than soaking, which is also common in SERS
literature – was chosen to mirror the potential end-use of plasmonic paper as swabs. One sample
of each drug was also prepared on a hole punched from an unmodified Whatman filter paper. All
of these were dried in air for a minimum of 5 min, then loaded into the sample holder. At this
point, Raman spectra were collected while adjusting parameters of laser power, acquisition time,
and extent of averaging.
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For the optimized collection of Raman spectra, power output was set to 10 mW. Spectra
were collected from three areas on each paper punch, while using the previously described
rastering device. Each spectrum was recorded as the average of three 10 s acquisitions.
(b)

(a)

(d)

(c)

(e)

Figure 7. Representative drug compounds used in this study. 2C-B (a), cocaine (b), fentanyl
(c), hydrocodone (d), and JWH-018 (e), chosen to represent several classes of controlled
substances: phenethylamines, traditional drugs of abuse, synthetic opioids, abused
pharmaceuticals, and synthetic cannabinoids, respectively.

SERS Limits of Detection
Calibration curves were generated for SERS response of each of the five drugs on
plasmonic paper. Five serial dilutions, each with a 1:4 dilution factor, were prepared from the 1
mg/mL stock solutions. Spectra were taken after the addition of 1 µL methanol, then after the
sequential additions of 1 µL from each dilution, beginning with the lowest concentration. Thus,
the amount of deposited drug progressed from ~1 ng to ~1.3 µg. The experiment used three
separately prepared plasmonic papers – fifteen paper punches were taken from each paper (three
for each drug). Each SERS spectrum was collected as the average of three 10 s integrations, with
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the laser output set to 10 mW. Three spectra were collected per paper punch, with the laser
rastering during acquisitions. To construct the plots, the intensity of a prominent, analyte-specific
peak was plotted as a function of the total amount of deposited drug.
Density Functional Theory: Calculated Spectra
Averaged spectra of 333 ng of deposited drug, besides their role in LOD calculations,
were also considered separately for comparison to simulated spectra. These were calculated
using density functional theory (DFT). All calculations were performed in Gaussian 2009, using
the B3LYP functional and with the basis set 6-311++G(d,p). Calculated frequencies were scaled
by a factor of 0.9679,90 then offset from the SERS spectra for comparison.
Discrimination among Isomers Using SERS
Two sets of isomers were selected, which had been demonstrated to be indistinguishable
by MS and tandem MS: three isomers of the synthetic cannabinoid JWH-018, as well as two
tryptamine derivatives – psilocin and bufotenine (from psychedelic mushrooms and the genus
species toad, respectively). Chemical structures of these compounds are shown in Figure 8.
Spectra were collected as in the previous experiment, from three regions of each paper
punch, after the addition of 1 µg drug. Each isomer was represented on nine total punches (taken
from across three individually prepared plasmonic papers). DFT spectra were calculated for each
drug compound, using the same parameters as previously noted.
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(a)

(b)

(c)

(d)

(e)

Figure 8. Structural and positional isomers selected to assess SERS discriminating power. The
two sets utilized were the tryptamine derivatives psilocin (a) and bufotenine (b), as well as
compounds related to JWH-018: N-1,1-dimethylpropyl (c), 2’-naphthyl (d), and 2’-naphthylN-1,1-dimethylpropyl (e) isomers.

SERS-PSI-MS Error-rate Study
Method Validation
The previously outlined procedure for collecting SERS after PSI-MS on the custom stage
was evaluated in a series of experiments, which included a mock error-rate trial (N = 50). SERS
spectra in this trial were collected as the average of six 15 s acquisitions, with the laser output at
10 mW. Samples were randomly prepared, as negative or with one of the five representative
drugs. The amount of applied drug was 50 ng in the case of 2C-B, cocaine, fentanyl, and
hydrocodone – and 200 ng in the case of JWH-018, which had a higher detection limit for both
techniques.
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Error-rate Study
The discriminatory capabilities of the combined SERS-PSI-MS platform were tested in a
larger error rate study (N = 500). All operating parameters were the same as previously noted,
except that the laser output was increased to 15 mW. All samples were randomly prepared in like
fashion to the mock trial, with 80 samples of each analyte and 100 negatives. Plasmonic papers
were freshly prepared every two days, and samples were prepared and analyzed in 25 sets of 20
samples. A blank was loaded before each sample and analyzed by both methods. Throughout the
study, documentation was made for the dates on which plasmonic papers had been prepared,
loaded with analytes, and analyzed.
All spectra were visually interpreted by experienced users. When SERS and PSI-MS
results did not agree (i.e., an ambiguous result), a second and third test were performed. If either
of these retests brought forth further ambiguity, the method was considered to have erred.
Variability in SERS performance (intra- and inter-day) was calculated as the percent relative
standard deviation (%RSD) of a selected peak-to-peak ratio. These ratios served as crude
approximations of the ability of the plasmonic papers to produce a consistent spectral fingerprint.
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CHAPTER III: RESULTS & DISCUSSION
SERS Detection of Drugs
Optimizing SERS Sensing on Plasmonic Papers
The first objective within this work was to optimize the collection of SERS spectra for
controlled substances deposited on plasmonic papers. This involved varying the laser power,
acquisition time, and extent of sample averaging. Plasmonic papers were used as received from a
collaborating laboratory.
Laser power output within the range of 10 – 15 mW (for a spot size of ~.008 mm2) seemed
to offer the best balance between maximizing intensity while reducing damage to the substrate.
The latter issue is seen in changes to the background features when the output was reached 20
mW (Figure 9). Furthermore, it was consistently found that acquisition times of at least 10 s were
needed to obtain appreciable signals, while acquisitions lasting longer than 30 s were deleterious
in the case of some drug analytes. This is because of fluorescence contributions, which are nearly
ubiquitous in Raman spectra. Fluorescence signals are typically removed mathematically; at
longer acquisition times, however, fluorescent photons bleach the detector.
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Normalized Intensity

40 mW

20 mW

10 mW

5 mW

Raman shift (Δcm-1)

Figure 9. Optimization of power settings for the 785 nm Raman excitation laser on dry
plasmonic paper. The 10 mW spectrum is similar to the 5 mW spectrum, but with less noise.
At 20 mW and above, however, the fingerprint begins to change – suggesting undesirable
photodegradation.

Averaging spectra has the effect of reducing the noise, scaling it by a factor of 1/√𝑛 (where
𝑛 = number of runs). Efficient noise-suppression can be facilitated by intra-scan averaging,
where each recorded spectrum is the average of multiple individual spectra. While extensive
averaging is desirable, a decision was made to restrict total collection times to between 30 and 90
s, in order to conform to the rapid analysis desirable in law enforcement settings. Thus, there
were typically 3 to 6 acquisitions averaged for each spectrum.
Collection from different spots on the plasmonic paper, even <1 mm apart, frequently
showed high variability in signal strength. This could presumably be caused in two ways. Firstly,
analyte could be unevenly distributed through the paper, as an artifact of pipetting known as the
coffee ring effect.91 When dissolved analyte is deposited on a surface, it disperses and dries such
that the perimeter of the wetted area has higher analyte concentrations than the center.
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The other cause of spot-to-spot variability is the uneven distribution of SERS hotspots – a
limitation in the plasmonic papers’ preparation. During soaking, the AuNPs adsorb and randomly
form aggregates on the cellulose fibers of the paper (Figure 3c). Hot spots result from aggregates
that possess the ideal size and geometry (which determine the SPR, as well as the adsorbed
species’ access to maximum electric field enhancement). However, visual discernment conveys
inconsistencies in AuNP loading: many sections on the top-sides of papers are tinted differently,
and a view of the bottom-sides reveals that the AuNPs penetrate the paper to different degrees
(Figure 10). Since plasmonic papers have been described as three-dimensional enhancing
substrates, these inconsistencies could easily sum to the observed signal fluctuations.

(a)

(b)

(c)

Figure 10. Image capturing the degree of homogeneity in AuNP loading on plasmonic paper,
both on the top, sensing side (a), and the bottom side (b). Uniformity can be improved upon
with increased experience pipetting colloid over the paper (c), but the aspect of uneven
penetration through the paper remains. These differences, along with the coffee ring effect, are
believed to be the main source of spot-to-spot variability in SERS signals.
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To minimize the spot-to-spot variations, the volume for additions of sample was set at 1
µL – an amount which would barely saturate a 3 mm-punched paper without welling up or
spilling over. Additionally, the previously described rastering apparatus increased the extent of
spot-to-spot averaging within each acquisition. As shown in Figure 11, rastering the laser led to
increases in signal strength and decreases to the variability among scans – both of which
favorably affected the signal-to-noise (S/N) ratio. These improvements are also promising for the
potential to compile a spectral library, in order to eventually identify substances by spectral

Intensity (arb.units)

matching.

(a)

998

cm-1,

(b)

I = 497

998 cm-1, I = 622
S/N = 75

S/N = 12

Raman shift (∆cm-1)

Raman shift (∆cm-1)

Figure 11. Raman acquisitions collected from a punch of plasmonic paper, loaded with 1 µg
fentanyl. Spectra were collected from three areas, both with the laser stationary (a) and
rastering (b). The S/N ratio was calculated by dividing the intensity of the 998 cm-1 peak by
the standard deviation of the baseline at its left (940 cm-1). Overall, rastering the laser led to an
appreciable increase in the S/N ratio.

SERS of Representative Drugs
Using the optimized collection parameters, Raman spectra were obtained for 1 µg of each
drug, deposited separately on three punches of plasmonic paper and one punch of unmodified
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filter paper. Spectra were collected in three regions of each punch and averaged together
(Nplasmonic = 9, Nunmodified = 3). The results are displayed in Figure 12, where each spectrum is
normalized and offset to aid in visualization of the different Raman shifts and relative intensities.

Plasmonic Paper

Unmodified Paper
(a)
2C-B

(b)
cocaine

(c)
fentanyl

(d)
hydrocodone

(e)
JWH-018

Figure 12. Normalized, offset Raman spectra of 1 µg each of 2C-B (a), cocaine (b), fentanyl
(c), hydrocodone (d), and JWH-018 (e) on 3 mm-punches of unmodified Whatman filter paper
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(left) and plasmonic paper (right). There are no distinguishing features among the spectra
collected from unmodified papers, while plasmonic papers show distinct, analyte-specific
Raman shifts.

There are a multitude of peaks exclusive to the respective analytes on plasmonic paper
samples, while spectra obtained from analyte applied to unmodified papers are indistinguishable
from one another. Each SERS spectrum is distinct, representing a sought-after molecular
fingerprint, specific to each drug. In terms of sensitivity, the indication is that 1 µg of drug,
dispersed through a 3 mm-punched paper, can readily be identified with SERS. If the drug is
assumed to be evenly spread within the paper, the amount surveyed by the laser scales to ~1 ng
during each acquisition (Apunch / Alaser spot ≈ 1000).
Spot-to-spot and Batch-to-batch Reproducibility
Consistency of performance on the paper SERS substrates was evaluated for each
analyte. The results are summarized in Table 3. Figure 13 shows overlaid fentanyl spectra (spotto-spot and batch-to-batch), presented both as absolute and normalized intensities.
Table 3
Reproducibility of SERS response on plasmonic paper by drug
Drug

Peak monitored (cm-1)

Spot-to-spot (%RSD)

Batch-to-batch (%RSD)

2C-B

1292

7.6%

16.0%

Cocaine

1000

9.5%

12.2%

Fentanyl

1000

9.0%

16.5%

Hydrocodone

1272

6.0%

8.9%

JWH-018

1334

6.8%

7.9%
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Figure 13. Overlaid SERS spectra for 333 ng of fentanyl, collected from different locations on
a single plasmonic substrate (a, b) and three independently prepared substrates (c, d). Spectra
at left display the absolute counts for each spectrum, while the same spectra are normalized at
right, clearly indicating that – though different spots and substrates yield different degrees of
enhancement – the analyte-specific relative intensities are very consistent.

For all analytes, there is an exceptional spot-to-spot reproducibility, with %RSD < 10%.
As previously discussed, the rastering apparatus was used in these acquisitions – this has been
shown to bs a key factor for the spot-to-spot performance. The batch-to-batch variations, though
higher, are not prohibitive. Perhaps most significantly, however, normalizing spectra makes them
nearly superimposable. This makes the consistent performance of a library-matching system
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more likely, and – if an appropriate internal standard is included – does not compromise the
potential for quantitative detection.
Limits of Detection
Sequential additions of drug to punches of freshly prepared plasmonic papers were
evaluated by SERS to construct calibration curves. Three papers were utilized, which had all
been separately prepared from the same, fresh batch of colloidal AuNPs. Limits of detection
(LODs) were calculated by plotting the intensity of a single, prominent analyte-specific peak as a
function of the amount of deposited drug analyte – a logarithmic equation was then used to fit
each plot. The LODs are presented in Table 4, alongside those from plasmonic PSI-MS analysis.
Spectral data and calibration curves are presented in Figures 14 – 18. Since SERS and PSI-MS
experiments were conducted using different sizes of paper, LODs are also presented in a form
that takes the area of paper into account (ng/mm2). Overall, the sensitivities of both techniques
indicate that coupled SERS-PSI-MS – barring unanticipated incompatibilities – would achieve
similar sensitivity, at the level of tens of nanograms.

Table 4
Limits of detection for each of the representative drugs on plasmonic paper
Drug

LOD (SERS)

LOD (PSI-MS)

2C-B

3.8 ng (0.53 ng/mm2)

25 ng (0.69 ng/mm2)

Cocaine

0.6 ng (0.08 ng/mm2)

13 ng (0.36 ng/mm2)

Fentanyl

1.0 ng (0.14 ng/mm2)

10 ng (0.28 ng/mm2)

Hydrocodone

3.7 ng (0.53 ng/mm2)

20 ng (0.56 ng/mm2)

JWH-018

26 ng (3.7 ng/mm2)

130 ng (3.6 ng/mm2)
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It is common in SERS literature to use the intensity of an analyte’s most prominent peak
(or the area under it) to calculate limits of detection. However, such a method is applied for
compounds (e.g. 4-nitrobenzenethiol, a.k.a. NBT) that are known to readily bind plasmonic
surfaces (via strong Au—S interactions) and elicit intense Raman scattering (from symmetric
NO2 stretching, for example). The analytes in this work do not behave in such an ideal manner,
and often compete closely with signals that are already present in the spectrum of blank
plasmonic paper. These background signals are quite appreciable across the region of 1200 –
1700 cm-1 – therefore, the most prominent analyte peaks outside of this range were selected for
LOD calculations.
Raman is a bulk technique for which signals scale linearly with the number of molecules
being analyzed. SERS operates similarly, yet, signals are expected to plateau as analyte achieves
monolayer coverage on the plasmonic surfaces. In a full calibration model for SERS, there is
expected to be an S-profile, progressing from below the LOD, to the linear range, and finally the
point of signal saturation. Notably, it is common in SERS literature to use log or semi-log plots
to extend the linear (empirical) range.62,92
All of the calibration curves display a saturation profile, wherein signals begin to plateau
after an initial sharp increase. The inlaid plots are well fit by logarithmic functions, though 2C-B
is an exception. The fit for 2C-B seems confounded by the point at 83 ng, which has a %RSD of
23% – among the highest. Hydrocodone, which, like 2C-B, seems to display the S-shaped
profile, also has a high degree of variability among the nine scans collected. Perhaps these
compounds merit further data collection, especially since exclusion of the 83 ng point results in
the appearance of good conformity to the other drugs’ calibration profiles. For fentanyl, and
perhaps cocaine, there is no deviation from the logarithmic best-fit, and the empirical range
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continues to 1.3 µg. It was not experimentally feasible to extend the data set: the DEA-exempt
samples were 1 mg in 1 mL solvent, and, deposited in 1 µL quantities, this would have been very
tedious. JWH-018, obtained as 5 mg, could easily be examined in larger quantities. At 10.3 µg
there was still no plateau from the empirical range.
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Figure 14. Overlaid SERS spectra and calibration curve for 2C-B.
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Figure 15. Overlaid SERS spectra and calibration curve for cocaine.
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Figure 16. Overlaid SERS spectra and calibration curve for fentanyl.
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Figure 17. Overlaid SERS spectra and calibration curve for hydrocodone.
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Figure 18. Overlaid SERS spectra and calibration curve for JWH-018.

There are indications for extending the range of these experiments to less than 1 ng.
Specifically, the LOD for cocaine had to be extrapolated, and none of the compounds failed to
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produce signal at 5 ng (the second-lowest increment examined). Thus, it may be prudent to
repeat the experiments, instead initiating depositions of analyte at the level of tens of picograms.
However, improving the processing of data by using multivariate statistical tools could prove
equally (if not more) useful.62 The limitations of a univariate approach to spectral data are
delineated below within the context of plasmonic papers’ background signals.
There is a complex interplay between background and analyte signals. A model case is
shown in Figure 19, using data from 2C-B. At five nanograms, the peak at 1290 cm-1 has grown,
while the entire region c.a. 1450 to 1600 cm-1 has been suppressed. Then at 83 ng the 1290 cm-1
peak has continued to rise, and – while the region from 1450 to 1550 cm-1 has continued to
decline – analyte-specific peaks from 1550 to 1600 cm-1 have gained prominence.
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Figure 19. Truncated, overlaid spectra of plasmonic paper with no analyte (grey trace), 5 ng 2CB (dark red trace), and 83 ng 2C-B (red trace). show the complicated interplay between
background suppression and increasing analyte signal. With additional sample, analyte-specific
peaks increase (a), background signals decrease (b), and regions where background and analyte
signals overlap decrease, then increase (c). A univariate analysis severely limits the utilization of
such trends for quantitative analysis.

There is adequate theoretical basis for these signal fluctuations – non-analyte molecules
are present on the surfaces of AuNPs and are gradually displaced by analyte. Citrate is a likely
candidate for this initially adsorbed species, since it is used in AuNP synthesis and stabilizes the
AuNPs in suspension. Figure 20 shows the outcome of an experiment wherein 1 µg of aqueous
trisodium citrate was deposited on plasmonic paper. For this amount of analyte, all of the small-
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molecule drug compounds studied showed appreciable spectral fingerprints. However, the
relative lack of change in SERS response with addition of citrate supports the notion that it
contributes to the Raman fingerprint of the blank (i.e., no analyte) plasmonic paper. Cellulose
perhaps also plays a part, since the background shares the profile of some peaks from unmodified

Intensity (arb. units)

paper (e.g. 1290, 1336, and 1376 cm-1).

withadded
addedcitrate
citrate
with
drypaper
plasmonic paper
dry

Raman shift (Δcm-1)
Figure 20. Normalized SERS response of plasmonic paper before and after the deposition of
trisodium citrate. The lack of change in the position and relative intensities of peaks suggest
that citrate could be responsible for the background signals frequently observed on plasmonic
paper.

If background signals were present as sharp, distinct peaks – removed from analyte
signals – one of them could be utilized as an internal standard. As seen, this is not the case. This
is not a limitation in the data, however, but a limitation in univariate (single-peak) analysis.
Using more sophisticated, multivariate statistical tools, several peaks – or the entire spectrum –
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could be utilized. Such tools can deconvolute spectra into the separate contributions of analyte
and background species, allowing a comparison between the two for quantitative purposes.
Using such means could perhaps correct other disparities in the calibration plots, for example,
the onset of signal prior to the calculated LOD for JWH-018.
Conformity to Calculated Spectra
The accuracy of each drug spectrum was assessed via its conformity to predicted Raman
fingerprints. These were calculated using density functional theory (DFT) – a computational tool
frequently used in SERS research. DFT describes many types of calculations, all of which arrive
at a system’s energy quanta as a function of electron density. This is in contrast to the
Schrödinger equation (Ĥ Ψ = E Ψ), which arrives at these energy quanta as a particular function
(the Hamiltonian operator, Ĥ) of all the positional coordinates for a system’s electrons (denoted
as Ψ). DFT has the advantage of being more accurate than the simplest approximation of the
Schrödinger equation (Hartree-Fock theory). Though corrections to HF greatly improve its
accuracy, surpassing that of DFT, these corrections require additional – often prohibitive –
computational time.
As previously mentioned, DFT calculations were carried out using the functional B3LYP
with a 6-311++G(d,p) basis set, and frequencies were scaled by a factor of 0.9679 – all of these
parameters are frequently attested in literature.90,93 SERS and DFT spectra for each of the five
drugs are normalized and offset in Figure 21.

44

(a)

774

(b)

770

Intensity (arb. units)

1270

1020

689

848

1000
882

829 875

1000

(c)

985

1288

1266

1024

704

985 1014

1589

1014 1154

1589

1183

1198 1268

1194

765

1700

1582

1247

1336

666

1722

1024 1172 1194

608

664

1583

1596

(d)

(e)

1299

1024

624

772

1592

1336

1426

1322

1427

1598

1607

1366 1512

1566

1014
1003

1328

1345

1502

1560

Raman shift (Δcm-1)
Figure 21. DFT-calculated spectra overlaid with SERS spectra for each drug compound. From
top to bottom are 2C-B (a), cocaine (b), fentanyl (c), hydrocodone (d), and JWH-018 (e), with
several corresponding peaks labelled for each set. The close agreements further demonstrate
the potential for using plasmonic papers to obtain accurate molecular fingerprints for trace
levels of analyte. Calculated spectra can also assist in identifying the particular vibrations
responsible for each peak in the Raman spectrum.
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The experimental and simulated spectra show very close agreement, with some
qualifications. Fluctuations in relative intensities (most pronounced in the case of hydrocodone)
are to be expected. This is because the enhancement of a vibration’s Raman scattering depends
on the proximity and orientation of the pertinent bonds relative to the gold surface. Thus, the way
in which molecules are packed on AuNPs causes some vibrational frequencies to be enhanced
more than others. Additionally, peaks could be broadened insofar as molecules display a range of
orientations on the plasmonic surfaces. Hydrocodone is a rigid, highly conjugated molecule –
compared with the other analytes it has a lack of freely rotating bonds. This may cause it to adapt
a restricted preferred orientation on the AuNP surface, leading to more pronounced alterations in
relative intensities.
Another aspect of this divergence pertains to vibrational frequencies. These DFT
calculations were performed for single molecules in vacuum. Interactions of the analyte
molecules with one another, as well as any tethering of molecules to AuNP surfaces, are
unaccounted for. Yet, these interactions can greatly affect the vibrational frequencies; differences
between simulated and experimental Raman frequencies are commonly attested.94 All this
considered, there is excellent agreement between the DFT-calculated and SERS spectra. Nearly
all the major peaks predicted in the former are present within 20 cm-1 in the latter.
SERS Discrimination of Isomers
Accurate identification of isomeric compounds is difficult in MS. Even when equipped
with tandem MS capabilities, a mass spectrometer cannot distinguish between species with
similar fragmentation patterns. Raman/SERS, on the other hand, derives signal from the unique
vibrational energy quanta of molecules. Thus, changes in a functional group’s position or
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rearrangement of alkyl chains can be readily identified. The respective MS and Raman/SERS
analyses of the isomers examined in this work are shown in Figures 22 and 23.

205 [M + H]+

160
205

(a)

(b)

solvent
m/z

m/z

(c)

Raman shift (Δcm-1 )

(d)

Raman shift (Δcm-1 )

Figure 22. The tryptamine derivatives psilocin (red) and bufotenine (blue) (a). MS and tandem
MS analyses (b) provide no distinction between the two. While the overlap between DFT (c)
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and SERS spectra (d) is not very strong, discrimination between the two compounds is facile
in either case. The regions highlighted in red reflect some possible similarities between the
predicted and experimental fingerprints.

Psilocin and bufotenine are structural isomers where the hydroxyl group occupies
different positions on the benzene ring (Figure 22a). The mass spectra of psilocin and bufotenine
are superimposable, showing only the protonated molecule at 205 m/z (Figure 22b). The same is
true for the tandem mass spectra, which show a single peak at 160 m/z, corresponding to the loss
of the dimethylamine fragment (Figure 22b). The DFT spectra predict a facile distinction (Figure
22c), though the accuracy of the simulated spectra is inferior to those of the five compounds
previously surveyed (Figure 21). Despite these inaccuracies, however, the experimental SERS
spectra (Figure 22d) are repeatably easy to distinguish (N = 9, across three independent
substrates). The differing vibrational frequencies, the ways in which psilocin and bufotenine
pack onto the plasmonic surfaces, and perhaps the preferred orientations of each molecule (only
psilocin can form internal hydrogen-bonds) give rise to very distinct SERS fingerprints, with
some regions – highlighted in red – resembling the calculated fingerprints. The relatively broad
SERS peaks could be attributable, as previously mentioned, to a distribution of the molecules’
orientations on the gold surfaces.
For JWH-018 and its isomers (Figure 23), MS and tandem MS spectra again show no
distinctions (Figure 23b). There are, however, different DFT and SERS spectra for each
compound (Figure 23c, d). Some of these differences can be attributed to specific structural
elements, as in the case of the 1’-naphthyl (grey, black) versus 2’-naphthyl (blue, red) species.
Relative to the former, the latter compounds have a red-shifted peak in the 1300 cm-1 – 1400 cm-1
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range (naphthalene C=C stretching). Several other small differences, specific to 1’-naphthyl and
2’-naphthyl species, are present across the entire fingerprint. Though such distinctions are not
easy to make among the N-1,1-dimethylpropyl (black, red) and N-pentyl species (grey, blue),
each compound nevertheless has a unique experimental SERS fingerprint. As before, the ability
to discriminate among such isomers is unique to Raman/SERS. This adds to its value as a
compliment to MS on an integrated, field-based sensing platform.
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(a)
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342 [M + H]+
155
342
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(d)

Raman shift (cm-1)
Figure 23. Isomers of JWH-018 (a): N-1,1-dimethylpropyl isomer (black), 2’-naphthyl isomer
(blue), and 2’-naphthyl-N-1,1-dimethylpropyl isomer (red). MS and tandem MS spectra (b) are
indistinguishable, while simulated (c) and experimental (d) Raman/SERS spectra show similar
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– but still distinct – fingerprints for each of the four compounds. DFT and SERS of
underivatized JWH-018 (grey) is also shown.

SERS-PSI-MS
Having established the potential of SERS detection on paper substrates, the method was
finally coupled with PSI-MS. At the outset, dual-method detection had to be optimized. Among
the weightier aspects of this process was the decision to collect SERS spectra before, during, or
after PSI-MS. Coupled analysis, where SERS data was collected at all three stages, was
performed for all five representative compounds.
Figure 24 reveals a characteristic outcome of coupled analysis, with SERS spectra
collected before, during, and after PSI-MS. Since the analyte – in this case 100 ng of 2C-B – was
dispersed through the paper, the SERS spectrum collected before PSI-MS analysis (Figure 24a)
had strong background features. Still, 2C-B was identifiable based on the presence of some of its
characteristic peaks (474 cm-1, 1290 cm-1). SERS intensity dropped off considerably during PSIMS analysis (Figure 24b) – which is justifiable on the basis of molecules having desorbed from
the plasmonic surfaces in the presence of spray solvent. SERS analysis conducted after PSI-MS
analysis (Figure 24c) brought forth an unexpected result – a 2C-B fingerprint of excellent
quality, with little to no persistence of background peaks (such as the shoulder peak at 1500 cm-1
and the isolated, broad peak at 1160 cm-1, seen in Figure 24a). PSI-MS analysis identified 2C-B
based on its protonated molecule and characteristic fragments (Figure 24d, e).
The drastic improvement in the analyte’s SERS fingerprint following PSI-MS suggests
that analyte adsorption onto the plasmonic surfaces was facilitated by the PSI-MS process. A
possible explanation is that the AuNPs are cleaned of pre-adsorbed molecules, while analyte is
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preconcentrated at the paper’s tip. This preconcentration – resulting from bulk movement of
analyte as solvent wicks through the paper – is consistent with published findings for both PSIMS and SERS.68,95 Though current access to instrumentation did not allow for a rigorous
investigation of this phenomenon, mapping of the plasmonic papers with a Raman microscope
could probe the bulk movement of analyte, possibly allowing optimization of the process as a
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Figure 24. Representative data for SERS-PSI-MS, collected from 50 ng of 2C-B on plasmonic
paper. SERS collected before (a) and during PSI-MS (b) are of inferior quality to that collected
after (c), where characteristic drug peaks are sharper and undesirable background peaks are
absent. MS and tandem MS spectra (d, e) are satisfactory for identification purposes, showing
the protonated molecule and characteristic fragments, respectively.

Pre-PSI versus post-PSI SERS analysis was performed for each of the five analytes
(Figure 25). Similarly to before, all post-PSI-MS SERS spectra were of very high quality.
Furthermore, data collected during this phase of experiments suggested that the LODs for SERS
could be lowered through performing coupled analysis with SERS collected after PSI-MS. As an
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example, Figure 25c shows the spectrum of 15 ng fentanyl on PSI-cut paper, which, at ~0.4
ng/mm2, is very close to its SERS detection limit of 0.14 ng/mm2. SERS collected pre-PSI-MS
shows no fingerprint for fentanyl, but collection post-PSI-MS yields a striking fentanyl spectrum.
It is also notable that, in the case of hydrocodone (Figure 25d), the absolute intensity of the
SERS spectrum collected post-PSI-MS was lower than that collected before. Even in this case,
however, the analyte fingerprint was much clearer and easier to identify post-PSI-MS.
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Figure 25. Plasmonic, PSI-cut paper with SERS analysis conducted before and after PSI-MS
for all five drugs. Pre-PSI-MS SERS analysis (black traces) was consistently inferior to postPSI-MS SERS analysis (red traces) for identification purposes. Drug was deposited as 50 ng in
the case of 2C-B (a), cocaine (b), hydrocodone (d), and JWH-018 (e), while – in order to probe
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the potential for lowering LODs – only 15 ng was deposited for fentanyl (c). It is notable that
the absolute intensity of SERS spectra could decrease post-PSI, as in the case of hydrocodone.
Still, the analyte fingerprint was easier to identify post-PSI in every case.

Having determined that SERS spectra were far more useful when collected post-PSI, the
staging for integrated analysis was constructed to reflect this. A vertical and translational
micrometer had already been acquired and integrated into prototypical stage designs. These were
then supplemented with 3D-printed components to allow rapid transitioning from PSI-MS to
SERS analysis.
Briefly, the updated stage contained a central channel, wherein paper samples, held in
printed, polypropylene strips, could slide back and forth, from the mass spectrometer inlet
(Figure 6, left) to the focal point of the Raman laser (Figure 6, right). Since the Raman laser was
firmly fastened above the stage, there was no need for focusing prior to acquisitions. The two
micrometers could be used to adjust the position of the entire stage, in order to obtain a stable
electrospray for each sample. Strips could easily be removed and replaced with new plasmonic
paper samples. These updates substantially improved throughput, from ~15 min/sample on the
former prototype to ~2 min/sample.
Error-rate Study
Twenty-five sets of 20 samples (N = 500) were prepared and analyzed blind. SERS
spectra were interpreted as positive for drug based on the visual discernment of a drug analyte’s
fingerprint, while the lack of any such fingerprint resulted in a negative interpretation.
Specifically, each drug was identified by the presence and consistent relative intensities of the
SERS peaks listed in Table 5 for each drug.
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Of the 500 samples, only four required a retest due to conflicting SERS and PSI-MS
results. Of these, three were successfully confirmed by retesting, while one returned further
ambiguity. For the combined technique, this corresponds to a false negative rate 0.2%.
Performing only one test of each sample returned a success rate of 99.2% overall, and there were
no false-positives.
To assess consistency of SERS performance across the study, a ratio between the two
most prominent analyte-specific peaks was taken to represent the overall spectral fingerprint for
each drug molecule. The average and standard deviation of this ratio were calculated for each
drug, on each day. The intra-day variability was evaluated as the relative percent standard
deviation (%RSD) of the ratio within a given day. For example, the pertinent peaks for
hydrocodone – 1272 cm-1 and 1436 cm-1 – had an intra-day variability ranging from 1.2% – 27%.
The inter-day variability was calculated as the %RSD of the average SERS intensity collected
from each day. Table 5 summarizes the SERS intra- and inter-day variabilities for each drug.

Table 5
Intra-day and inter-day variabilities in SERS drug identification performance for coupled SERSPSI-MS analysis
Drug

SERS peak ratio
(cm-1/cm-1)

Range of intra-day
variability

Average intra-day
variability

Inter-day
variability

2C-B

1290 / 474

0.29 – 41

15

15

Cocaine

998 / 886

0.13 – 32

12

15

Fentanyl

998 / 742

0.10 – 25

13

18

Hydrocodone

1272 / 1436

1.2 – 27

11

15

JWH-018

1336 / 772

0.39 – 11

6.2

7.9
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CHAPTER IV: CONCLUSIONS AND OUTLOOK
SERS sensing on plasmonic paper substrates has herein been successfully piloted as a
compliment to PSI-MS for the analysis of trace drug residues. Proof-of-principle investigations
demonstrated SERS detection for five controlled substances, chosen from among common and
emerging drug classes. All the SERS fingerprints showed good conformity to DFT-calculated
Raman spectra. Calibration models were constructed for each drug, which placed the LODs
primarily in the single-nanogram range – comparable sensitivity to portable PSI-MS for the same
analytes. Excellent selectivity – surpassing PSI-MS – was demonstrated in the analysis of
isomeric compounds. Different parameters for integrated SERS-PSI-MS analysis were
compared, and a standard operating procedure was developed. This procedure was guided by the
noteworthy finding that SERS spectral quality was significantly improved when this technique
was performed after the PSI-MS process. High-throughput integrated analysis was achieved
using a custom-built stage with 3D-printed supports and sample strips. Finally, an error rate
study of 500 samples, each containing sub-microgram quantities of drug, produced a 99.8%
success rate.
Several findings in this research merit further study. Among these, the preparation of
plasmonic substrates deserves attention. While background signals tended towards a consistent
fingerprint, there were frequent, seemingly batch-specific deviations. Of these, some background
signals were so strong as to severely obscure the presence of a drug’s spectral fingerprint. Since
the preparation of papers took a full 24 hours, time limitations (e.g., during the error rate study)
did not allow the rejection of batches by way of quality control.
Beyond optimizing the current process of soaking papers in citrate-reduced AuNPs, there
are ample alternate methods for preparing plasmonic papers.63 Several of these preparations

57

involve no added constituents relative to the current process (requiring only Au or Ag salts and
reducing agent).78,80,96 Thus, such methods of preparation could feasibly be explored as
compatible with PSI-MS (by not introducing interfering substances), while perhaps improving
SERS performance (by way of higher enhancements, lower %RSDs, and better long-term
stability). By far the most helpful substrate would be one with consistent, predictable background
signals, as this would be a limiting factor in the success of building and implementing a librarymatching system.
Another worthy point of future study is the translation of plasmonic paper into a fieldable
sampling format. The current 3D-printed sample holders were designed to loosely resemble
swabs. This theme can be developed towards the realization of a useable 3D-printed, plasmonic
paper swab. An interesting, and underexplored, aspect of the current project was the use of
nanofibrous polymer membranes for SERS-PSI-MS. There is precedent for improving SERS and
PSI-MS separately using PLA (polylactic acid) nanofibrous membranes.97,98 Furthermore, PLA
is an affordable and widely available 3D-printing material. A combination of PLA nanofibrous
membranes and 3D-printed PLA swabs could be investigated as a highly versatile, field-ready
SERS-PSI-MS substrate.
Besides developments to the plasmonic substrates, the most immediate future work is the
incorporation of multivariate statistical tools to fully utilize SERS spectral data. Such tools are
very common in Raman and SERS literature, and enable generation of library-matching systems
and analysis of mixtures. For the latter, SERS enjoys no such selectivity as PSI-MS, which with
tandem MS capabilities can effectively eliminate all but the desired ions. Rather, SERS spectra
must be statistically deconstructed into the summed fingerprints of all the molecular species
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present. Multivariate statistical means of handling such data are needed to usefully situate SERS
alongside PSI-MS in the analysis of real-world drug samples.
Overall, SERS-PSI-MS has been demonstrated as a promising tool for modernizing
portable drug detection. With pursuit of the aforementioned points, particularly the multivariate
utilization of the SERS spectral data, the benefits of this dual-instrument platform could be
maximized, bringing it closer to the field and to real-world samples.
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